MyMD Pharmaceuticals Inc. (MYMD) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
855 N. WOLFE STREET BALTIMORE, MD 21205 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 4,923 | 4,836 | 11,559 | 35,336 | 9,682 | 5,455 | |||
| Cash and cash equivalents | 2,681 | 749 | 556 | 18,618 | 517 | 182 | |||
| Short-term investments | 2,242 | 4,087 | 11,003 | 16,718 | 9,164 | 5,273 | |||
| Receivables | 1,200 | 43 | 186 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 198 | 199 | 585 | ||||||
| Inventory | 198 | 199 | 585 | ||||||
| Prepaid expense | 893 | 566 | 1,106 | 294 | 387 | 444 | |||
| Disposal group, including discontinued operation | 12 | ||||||||
| Other undisclosed current assets | (198) | ||||||||
| Total current assets: | 5,816 | 5,402 | 12,665 | 36,843 | 10,311 | 6,670 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 47 | 140 | 149 | ✕ | |||||
| Property, plant and equipment | 34 | 83 | |||||||
| Long-term investments and receivables | 1,500 | 1,500 | 1,500 | ||||||
| Long-term investments | 1,500 | 1,500 | 1,500 | ||||||
| Intangible assets, net (including goodwill) | 10,499 | 10,499 | 10,499 | 170 | 243 | ||||
| Goodwill | 10,499 | 10,499 | 10,499 | ||||||
| Intangible assets, net (excluding goodwill) | 170 | 243 | |||||||
| Prepaid expense | 252 | ||||||||
| Other noncurrent assets | 3 | 12 | |||||||
| Other undisclosed noncurrent assets | 115 | 798 | |||||||
| Total noncurrent assets: | 12,046 | 12,138 | 12,148 | 574 | 1,137 | ||||
| TOTAL ASSETS: | 17,862 | 17,540 | 24,813 | 36,843 | 10,885 | 7,807 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 4,353 | 2,673 | 987 | 2,204 | 1,530 | 1,974 | |||
| Accounts payable | 3,716 | 2,673 | 987 | 2,204 | 1,530 | 1,974 | |||
| Accrued liabilities | 637 | ||||||||
| Deferred compensation liability | |||||||||
| Derivative instruments and hedges, liabilities | 61 | ||||||||
| Disposal group, including discontinued operation | 59 | ||||||||
| Due to related parties | ✕ | ✕ | 30 | ||||||
| Other undisclosed current liabilities | 574 | 66 | 53 | ||||||
| Total current liabilities: | 4,988 | 2,769 | 1,040 | 2,263 | 1,530 | 1,974 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 96 | ||||||||
| Liabilities, other than long-term debt | 101 | 76 | |||||||
| Deferred compensation liability, classified | 101 | ||||||||
| Operating lease, liability | 76 | 96 | ✕ | ||||||
| Other undisclosed noncurrent liabilities | (66) | ||||||||
| Total noncurrent liabilities: | 101 | 76 | 126 | ||||||
| Total liabilities: | 5,089 | 2,845 | 1,166 | 2,263 | 1,530 | 1,974 | |||
| Temporary equity, carrying amount | |||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | 12,370 | 14,695 | 23,647 | 34,579 | 9,355 | 5,834 | |||
| Common stock | 2 | 108,309 | 171,599 | 128,920 | 121,555 | ||||
| Additional paid in capital | 114,200 | ||||||||
| Accumulated other comprehensive income (loss) | 18 | (26) | |||||||
| Accumulated deficit | (101,977) | (93,759) | (78,562) | (137,164) | (119,583) | (115,695) | |||
| Other undisclosed equity, attributable to parent | 145 | 145 | 102,209 | 145 | |||||
| Other undisclosed equity | 404 | ||||||||
| Total equity: | 12,774 | 14,695 | 23,647 | 34,579 | 9,355 | 5,834 | |||
| TOTAL LIABILITIES AND EQUITY: | 17,862 | 17,540 | 24,813 | 36,843 | 10,885 | 7,807 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 54 | 1,577 | 1,666 | |||||
| Gain on disposition of assets for financial service operations | 54 | |||||||
| Cost of revenue | (19) | (47) | (94) | |||||
| Cost of goods and services sold | (19) | (1,098) | (1,538) | |||||
| Other undisclosed gross profit | (1,052) | (1,445) | ||||||
| Gross profit: | 35 | 479 | 127 | |||||
| Operating expenses | (13,311) | (14,588) | (13,165) | (12,286) | (4,425) | (10,017) | ||
| Other undisclosed operating loss | (3,812) | (695) | (15,645) | (35) | (171) | |||
| Operating loss: | (17,123) | (15,283) | (28,810) | (12,286) | (3,946) | (10,060) | ||
| Nonoperating income (expense) | 13,123 | 85 | (1,079) | 133 | (58) | 789 | ||
| Investment income, nonoperating | 456 | 84 | 9 | 82 | 98 | 181 | ||
| Loss from continuing operations before equity method investments, income taxes: | (4,000) | (15,197) | (29,889) | (12,152) | (4,004) | (9,272) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 116 | (1,577) | ||||||
| Loss from continuing operations before income taxes: | (4,000) | (15,197) | (29,889) | (12,152) | (3,888) | (10,849) | ||
| Income tax expense (benefit) | (4,129) | 5,914 | 6,219 | 1,958 | 738 | |||
| Other undisclosed loss from continuing operations | (1,958) | |||||||
| Loss from continuing operations: | (8,129) | (9,283) | (23,670) | (12,152) | (3,150) | (10,849) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (23,670) | (17,581) | (3,150) | (10,849) | |
| Loss from discontinued operations | (5,428) | |||||||
| Net loss: | (8,129) | (9,283) | (23,670) | (17,581) | (3,150) | (10,849) | ||
| Other undisclosed net income (loss) attributable to parent | 4,129 | (5,914) | (6,219) | (738) | ||||
| Net loss attributable to parent: | (4,000) | (15,197) | (29,889) | (17,581) | (3,888) | (10,849) | ||
| Preferred stock dividends and other adjustments | (4,218) | |||||||
| Other undisclosed net income available to common stockholders, basic | 21,698 | |||||||
| Net income (loss) available to common stockholders, diluted: | (8,218) | (15,197) | (29,889) | (17,581) | (3,888) | 10,849 | ||
Comprehensive Income ($ in thousands)
| 6/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (8,129) | (9,283) | (23,670) | (17,581) | (3,150) | (10,849) | ||
| Comprehensive loss: | (8,129) | (9,283) | (23,670) | (17,581) | (3,150) | (10,849) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (694) | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (8,129) | (9,283) | (23,670) | (17,581) | (3,844) | (10,849) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.